CMC Biologics Wins 2013 CMO Leadership Award for Innovation, Quality and Reliability
Published: Mar 19, 2013
SEATTLE and COPHENHAGEN, Denmark, March 19, 2013 /PRNewswire/ -- CMC Biologics, a global contract manufacturing organization known for its technical excellence in biopharmaceutical development and cGMP manufacture of protein based therapeutics, was recognized for innovation, quality and reliability by Life Science Leader at a prestigious ceremony at DCAT Week13 in New York last week.
"CMC Biologics is honored to receive this prestigious award and appreciate the recognition by Life Science Leader. Our goal is to provide our customers with the highest standards of quality and reliability in both manufacturing and development, and which is the foundation of our customers' clinical and commercial success," said Claes Glassell, Chief Executive Officer. "The entire CMC Biologics' team is committed to continued improvement throughout our operations, and to continually innovate to advance biopharmaceutical manufacturing to the next level."
Bringing new pharmaceutical products to market is time consuming and costly, thereby having reliable and effective contract organizations to work with helps streamline that process. The Life Science Leader CMO Leadership awards are designed to honor top performers based on survey responses from thousands of industry executives, conducted by Nice Insight, and to better serve biopharmaceutical executives in their CMO selection process. These data will help companies focus on potential CMO partners who can handle their projects and are considered most reputable in the industry. For more information visit: www.cmoleadershipawards.com.
About CMC Biologics
CMC Biologics is leading the industry among CMO's in reliability, technical excellence, and quality Right and On Time. With facilities in the USA and Europe, the Company is a global CMO that provides fully integrated biopharmaceutical development and manufacturing solutions to clients around the world. The Company has proven expertise in delivering custom solutions for the scale-up and cGMP manufacture of protein-based therapeutics for pre-clinical, clinical trials and commercial production. The Company's wide range of integrated services includes cell line development, bioprocess development, formulation and comprehensive analytical testing. Clients can also benefit from CMC Biologics' proprietary CHEF1® expression system for mammalian production. CMC Biologics has fully segregated microbial fermentation and mammalian cell culture suites and offers both fed-batch and perfusion production processes. CMC Biologics is located in Copenhagen, Denmark; Seattle, Washington; and Berkeley, California. More detailed information can be found at www.cmcbiologics.com.
SOURCE CMC Biologics